FaceHeart Corporation

FaceHeart Corporation develops FDA-cleared contactless video-based vital signs measurement software powered by artificial intelligence image recognition technology. The company's flagship product, FaceHeart Vitals™ (registered as FH Vitals SDK), is a Software as Medical Device (SaMD) that measures multiple vital parameters from a 50-second facial scan without requiring wearables or connected devices. The solution has received two FDA 510(k) Class II clearances: one for Heart Rate measurement (k223622) and one for Respiration Rate measurement (k243966). The platform measures heart rate, respiration rate, blood pressure, oxygen saturation, heart rate variability, stress index, and screens for atrial fibrillation. Additional biomarkers in beta development include HbA1c, hemoglobin, and cholesterol. FaceHeart Vitals™ is designed for seamless integration with diverse devices and platforms including mobile phones, laptops, desktops, digital picture frames, smart TVs, smart mirrors, security cameras, and robots, eliminating the need for proprietary hardware. Primary applications span telemedicine and remote healthcare (enabling spot checks, diagnostics, and triage), digital health and wellness applications, and smart device integration for both medical and consumer settings. The technology provides medical-grade accuracy trained on millions of datasets and is compatible with various platforms and operating systems. FaceHeart serves healthcare providers, telemedicine platforms, digital health application developers, and smart device manufacturers seeking to integrate contactless vital sign monitoring. The company has garnered industry recognition, including selection for the Forbes Asia 100 to Watch 2025 list and the MedTech Breakthrough Awards 2025 for Best Biometric Sensor Solution.